OBR – News, Perspective, Catalyst

Today's Oncology News

Opt In Search Archives

Myovant to Submit Lead Drug For Prostate Cancer Approva...

(BioPharma Dive) Nov 19, 2019 - Myovant Sciences said Tuesday a late-stage trial studying its lead drug in advanced prostate cancer met its pr...

Morphosys to Boost Size Of Tafasitamab Drug Trial On En...

(Reuters) Nov 18, 2019 - German biotech company Morphosys said more patients would be recruited for a study testing its most advanced drug aga...

The FDA Will Review Samsung Bioepis' Proposed Bevacizum...

(The Center For Biosimilars) Nov 19, 2019 - Samsung Bioepis announced Tuesday that the FDA has accepted for review the company’s Biologics L...

Featured Content

Suresh Ramalingam, MD, on how the FLAURA trial may impact care for EGFR-mutated NSCLC

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley Monk, MD, FACOG, FACS, Professor and Director of the Division of Gynecologic Oncology at Creighton University School of Medicine, discuss ovarian cancer clinical updates from ESMO 19

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Marwan Fakih, MD, Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, discuss colorectal cancer clinical updates from ESMO 19

Artificial intelligence (AI) has the potential to identify patients with cancer at high risk of unplanned utilization of acute care, a critical healthcare cost driver. OBR spoke with Cardinal Health’s Amy Valley, PharmD, on the opportunities and obstacles to implementing AI in identification of these high-risk patients.

Patient-reported outcomes (PROs) monitoring has been shown to have multiple benefits for cancer patients, while also representing an important tool for providers in implementing value-based care. We look at some of the steps needed to integrate PROs effectively and seamlessly into the electronic workflow and routine cancer care.

Podcasts

Colorectal Cancer – Marwan Fakih, MD, and Robert Figlin, MD, provide post ESMO ’19 clinical update

00:00

Listen on
Apple Podcasts

Listen on
Google Play

Listen on
Spotify

Title

Released

Ovarian Cancer – Bradley Monk, MD, and Robert Figlin, MD, provide post ESMO ’19 clinical update

10/10/19

Colorectal Cancer (CRC) - Scott Kopetz, MD, and Robert Figlin, MD, provide post World GI '19 clinical update

07/30/19

Hepatocellular carcinoma (HCC) - Daneng Li, MD and Robert Figlin, MD, discuss clinical highlights from ASCO 2019

07/02/19

Breast Cancer – Neelima Denduluri, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO 2019

06/21/19

Expert Video Insights

Search by

Ahmed Kaseb, MD, elaborates on the phase 1b study investigating atezolizumab + bevacizumab in HCC

Arndt Vogel, MD, offers his opinion on pemigatinib in the management of cholangiocarcinoma

OBR Green

View Archives

November 2019 Edition

Patient-reported outcomes (PROs) monitoring has been shown to have multiple benefits for cancer patients, while also representing an important tool for providers in implementing value-bas...

November 2019 Edition

Artificial intelligence (AI) has the potential to identify patients with cancer at high risk of unplanned utilization of acute care, a critical healthcare cost driver. OBR spoke with Card...

Blog

Third-Line Treatment in Metastatic Colorectal Cancer Po...

Oct 07, 2019

Targeted oral tyrosine kinase inhibitors (TKIs) have an established role in third-line treatment of metastatic colorectal cancer (mCRC), but an expert outlined an...

ESMO Opens with Survival Benefits from Long-Term Data i...

Sep 30, 2019

The 2019 European Society of Medical Oncology (ESMO) opened with a series of trials with positive overall survival (OS) data. Generally considered the gold standa...

Rapid Integration of Information Presented at 2019 ASCO...

Jul 15, 2019

Introduction OBR and MDoutlook are pleased to share excerpts from the most recent MDoutlook OncoPolls™ following this year’s ASCO annual meeting in ...

OBR Tools

Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.

Learn More

The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.

Learn More

Oncology Events Calendar

November 19, 2019

For Caregivers: Practical Tips for Coping with Your Loved One’s Lung Cancer During the Holidays (CancerCare Connect® Education Workshop)

[by phone or online via webcast]

December 3, 2019

For Caregivers: Practical Tips for Coping with Your Loved One’s Merkel Cell Carcinoma During the Holidays (CancerCare Connect® Education Workshop)

[by phone or online via webcast]

December 11, 2019

NCCN Patient Advocacy Summit: Delivering Value for Patients across the Oncology Ecosystem

Washington, DC

December 18, 2019

The Latest Developments Reported at the 42nd Annual San Antonio Breast Cancer Symposium (SABCS) (CancerCare Connect® Education Workshop)

[by phone or online via webcast]

January 9 - 12, 2020

OBR Radar

Top 5 Market Moving Events

Date	Company and Product
Dec 02	Roche , Tecentriq® (atezolizumab) + Abraxane® + carboplatin The company announced on Aug. 30, 2019 that the review period for the company’s sBLA for Tecentriq in combination with chemotherapy (Abraxane) and (carboplatin) for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumor aberrations had been extended by 3 months. The extension allows the FDA time to review additional information requested in support of the sBLA. The FDA is now expected to make a decision on approval by Dec. 2, 2019. In January 2019, the FDA accepted the sBLA based on results from the phase 3 IMpower130 study, which met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS).
Dec 07	Celgene , lisocabtagene maraleucel (aka liso-cel) At ASH Celgene will present safety and efficacy results from the pivotal TRANSCEND NHL-001 study of its investigational CD-19 targeted chimeric antigen receptor (CAR) T cell therapy liso-cel in relapsed/refractory large B-cell non-Hodgkin lymphoma (Oral presentation, Abstract #241; Saturday, December 7, 2019, 2:00 pm ET). Additional liso-cel data from three ongoing studies will evaluate the use of the therapy in an outpatient setting, as well as in transplant noneligible patients with relapsed/refractory large B-cell non-Hodgkin lymphoma (PILOT) and in patients with relapsed/refractory chronic lymphocytic leukemia (TRANSCEND CLL-004).
Dec 08	Roche , mosunetuzumab At ASH, Roche will present data from the phase 1/1b GO29781 study on mosunetuzumab, a CD20-CD3 T-cell engaging bispecific antibody, in people with poor prognosis NHL, including those who have had prior chimeric antigen receptor T-cell therapy, in a Plenary Session on Sunday, Dec. 8, 2019 (Oral Abstract #6, 2:00 - 4:00 pm ET).
Dec 09	Celgene / bluebird bio, bb21217 Celgene will present updated results from an ongoing phase 1 clinical study of bb21217, its second-generation anti-BCMA CAR-T therapy, in multiple myeloma at ASH (Oral presentation, Abstract #927; Monday, December 9, 2019 at 6:45 pm ET).
Dec 31	Karyopharm Therapeutics , Xpovio™ (selinexor) Xpovio was granted an accelerated, or conditional, approval by the FDA on July 3, 2019 in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies. The accelerated approval came despite an ODAC’s earlier recommendation on Feb. 26, 2019 not to approve the therapy due primarily to its significant toxicity issues. Continued approval for the indication is contingent on "verification and description of clinical benefit in a confirmatory trial." The phase 3 BOSTON study, a trial evaluating selinexor in combination with Velcade (bortezomib) and low-dose dexamethasone that aims to benefit patients with earlier stage multiple myeloma, will serve as the confirmatory trial, according to a July 3, 2019 press release. At the ODAC meeting in February, the panel recommended that the FDA postpone a final decision on approval until results from the BOSTON trial were in. A readout from BOSTON is due in late 2019. (See our July 3, 2019 Archived Radar entry also.)

OBR Finance

Top 5 Winners

	Last	Change	% △
ATNX	$15.53	4.09	+35.75%
BCRX	$2.03	0.33	+19.12%
CALA	$3.87	0.49	+14.35%
DRNA	$24.00	2.61	+12.18%
ARQL	$8.46	0.87	+11.40%

Top 5 Losers

	Last	Change	% △
AVEO	$0.62	-0.04	-5.64%
NYMX	$1.70	-0.09	-5.03%
GNBT	$0.96	-0.04	-4.00%
NWBO	$0.21	-0.01	-2.95%
LBIO	$5.69	-0.16	-2.74%

Today's Oncology News

Featured Content

Podcasts

Expert Video Insights

OBR Green

Blog

OBR Tools

Sponsored Content

Oncology Events Calendar

For Caregivers: Practical Tips for Coping with Your Loved One’s Lung Cancer During the Holidays (CancerCare Connect® Education Workshop)

ACCC Oncology Reimbursement Meeting | Georgia

20th Annual Meeting of the Society of Urologic Oncology

61st ASH Annual Meeting & Exposition

San Antonio Breast Cancer Symposium

For Caregivers: Practical Tips for Coping with Your Loved One’s Merkel Cell Carcinoma During the Holidays (CancerCare Connect® Education Workshop)

NCCN Patient Advocacy Summit: Delivering Value for Patients across the Oncology Ecosystem

The Latest Developments Reported at the 42nd Annual San Antonio Breast Cancer Symposium (SABCS) (CancerCare Connect® Education Workshop)

Advancing Precision Medicine Drug Development: Incorporation of Real World Data and Other Novel Strategies

26th ACE Annual Meeting (Association of Cancer Executives)

2020 Gastrointestinal Cancers Symposium (GI 2020) (co-sponsors: AGA, ASCO, ASTRO & SSO)

ASCO-SITC Clinical Immuno-Oncology Symposium

2020 Genitourinary Cancers Symposium (GU 2020) (co-sponsors: ASCO, ASTRO & SUO)

2020 Multidisciplinary Head and Neck Cancers Symposium (ASCO, ASTRO & SITC)

ACCC 46th Annual Meeting & Cancer Center Business Summit

The Annual Assembly of Hospice and Palliative Care 2020 (AAHPM & HPNA)

NCCN Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™

17th Annual Indy Hematology Review

AACR Annual Meeting 2020

2020 ASCO Annual Meeting

ACCC 37th National Oncology Conference

OBR Radar

Editorial Board Comments

OBR Finance